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Objective: This study was to investigate the synergistic growth inhibitory effect by combination of adenovirus 
mediated p53 gene transfer and cisplatin in ovarian cancer cell lines with different p53 gene mutation patterns. 
Methods: Three ovarian cancer cell lines, p53 deleted SKOV3, p53 mutated OVCAR-3, and PA-1 with wild-type p53 
were transduced with human adenovirus vectors carrying p53 gene (Ad-p53) and treated with a sublethal concen-
tration of cisplatin before and after Ad-p53. The cell number was counted daily for 5 days after Ad-p53 transduction. 
Western blotting was used to identify p53 and p21 protein expressions, and flow cytometric analysis was performed 
to investigate any change of DNA ploidy after Ad-p53 transfer.
Results: Ad-p53 transduced cells successfully expressed p53 and p21 proteins after 48 hours of Ad-p53 transduction. 
Synergistic growth inhibition by combination of Ad-p53 and cisplatin was detected only in SKOV3 and OVCAR-3 
cells, but not in PA-1 cells. In p53 deleted SKOV3 cells, cisplatin treatment after Ad-p53 showed higher growth 
inhibition than the treatment before Ad-p53 transduction, and reverse relationship was observed in p53 mutated 
OVCAR-3 cells. In SKOV3 cells, the fraction of cells at G2/M phase increased after cisplatin treatment, however, it 
decreased dramatically with Ad-p53 transduction.
Conclusion: The synergistic growth inhibition by combination of Ad-p53 and cisplatin may depend on the p53 status 
and the temporal sequence of cisplatin treatment, suggesting judicious selective application of this strategy in clinical 
trials.
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INTRODUCTION
Ovarian cancer is a malignancy with a poor prognosis, and 
the majority of patients have disease disseminated outside of 
the ovary at the time of initial diagnosis.1 Despite aggressive 
surgical debulking and introduction of platinum based che-
motherapy regimens, the mortality rate associated with this 
tumor remains high, and the overall 5-year survival rate is on-
ly approximately 11-25%.2 Because of the poor prognosis as-
sociated with this cancer, it has become imperative that new 
treatment modalities continue to be introduced and tested. In 
recent years, the use of gene therapy with adenoviral vector 
constructed to express the protein products of tumor sup-
pressor genes has received a great deal of attention. Because of 
its inherent death-inducing activity, and it's prevalent muta-
tion in 40-80% of ovarian tumors, the majority of gene ther-
apy research has focused on the p53 tumor suppressor gene.3-6
In the presence of chromosomal alterations, p53 up-regu-
lates not only p21-cyclin-cdk pathway that is essential in the 
transition from G1 to S phase of cell cycle, but also induces 
apoptotic pathway to programmed cell death.7-9 Restoration 
of p53 gene function by wild-type p53 gene transfer leads cells 
to G1 arrest and apoptosis, resulting in cell growth inhibition 
and death in vitro and in vivo.9-14 However, the gene therapy 
with the tumor suppressor gene alone has pitfalls. Aside from 
p53 gene mutations, most human cancer cells are known to 
have coincidental down-stream gene mutations involved in 
apoptosis or growth arrest. To overcome such limitations of 
gene therapy, a combination with conventional treatment mo-
dalities, such as chemotherapeutic agents or radiation, is sug-
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Table 1. The p53 status of three ovarian cancer cell lines
Cell lines p53 status Mutation
  SKOV3 Homozygous deletion
  OVCAR-3 Point mutation Codon 248 CGA (Arg)
 → CAG (Gln)
  PA-1 Wild-type
gested as a possible alternative strategy for human adenovirus 
vectors carrying p53 gene (Ad-p53) single gene therapy.15-17
Cisplatin, a cell cycle nonspecific DNA damaging agent, is a 
chemotherapeutic agent widely used in human ovarian 
cancer. Singularly, cisplatin is one of the most effective che-
motherapeutic drugs in advanced ovarian cancers with re-
sponse rates of 30-60%.18,19 A combination of Ad-p53 and cis-
platin is known to have not only additive cytotoxic effect on 
human ovarian cancer cells but also a synergistic manner, ren-
dering this combination as an effective gene therapy 
strategy.15-17 However, most of the studies have been per-
formed with limited number of ovarian cancer cell lines. 
Furthermore, a combination of Ad-p53 and cisplatin theoret-
ically may elicit different cytotoxic effect depending on p53 
gene status of cancer cells. However, questions of whether the 
synergistic tumor growth inhibition depends on p53 gene sta-
tus in the ovarian cancer cells have not been well studied. 
The temporal sequence of adminstration of Ad-p53 and cis-
platin is an another critical factor for this combination 
strategy. In several cancer cell lines including ovarian cancer, 
sequence of Ad-p53 administration followed by cisplatin is 
known to inhibit tumor growth more effectively than that of 
other dosing schedules.17,20 On the other hand, a recent study 
found that the reverse sequence was more effective in p53 de-
leted lung cancer cell lines in inhibiting growth compared to 
other dosing schedules.21 It appears, therefore, that the differ-
ential cytotoxic effect of Ad-p53 and cisplatin combination 
due to temporal sequence of adminstration depends on the 
type of cancer cells, and this differential effectiveness is an ex-
tremely important factor in clinical settings and should be 
clearly elucidated.
The mechanism of synergy with combination of Ad-p53 and 
cisplatin, however, is not well understood. With restoration 
of p53 function, cell cycle progression of the damaged cancer 
cells is checked at the G1/S phase and the cells are led to the 
apoptotic pathway and eventually cell death.7-9,22 However, 
the p53 gene has recently been shown to be a major factor in 
the G2/M phase cell cycle check point.23 Therefore, after DNA 
damage, cell arrest occurs at the transition of not only the 
G1/S phase but also the G2/M phase of the cell cycle, and the 
p53 gene in the G2/M phase cell cycle check point inhibits 
damaged cells from progressing to mitosis, thereby producing 
aneuploidy or polyploidy cells, which are known to be re-
sistant to chemotherapeutic agents.24-27 Therefore, there is a 
good possibility that DNA ploidy might be altered after p53 
gene transfer, and this could be one of the mechanisms in-
volved in the synergy of combination of Ad-p53 and cisplatin. 
In this study, we investigated the synergistic tumor sup-
pression effect of combination of Ad-p53 gene transfer and 
cisplatin in ovarian cancer cell lines with various p53 gene 




SKOV3 cell line with homozygous deleted p53 and PA-1 cell 
line with wild type p53 were maintained in DMEM (GIBCO, 
Grand Island, NY, USA) containing 10% fetal bovine serum 
(FBS), 100 U/ml penicillin and 100 μg/ml streptomycin. 
OVCAR-3 cell line with point mutated p53 was maintained in 
RPMI 1640 supplemented wild 10% FBS and insulin (Table 
1).28 The adenovirus stocks were propagated in the human 
transformed embryonal kidney 293 cell line, as described 
previously.29
2. Vectors
The replication defective human adenovirus vectors (from 
Dr. Robert Gerard, Southwestern Medical Center, Texas 
Univ., USA) were produced via homologous recombination 
between two transfected plasmids, pACCMVpLpV and pJM17, 
containing adenovirus DNA fragments overlapped at the E1A 
region. The expression cassette containing wild-type p53 
cDNA, driven by the cytomegalovirus (CMV) early enhancer 
and promotor followed by multiple cloning region and SV40 
polyadenylation signal, was inserted in place of the E1a 
deletion. To construct Ad-CMV-LacZ and Ad-CMV-Luc, cas-
settes containing the β-galactosidase and luciferase gene 
were inserted in place of the E1A region, respectively. 
The pACCMVpLpA and pJM17 were co-transfected to hu-
man 293 cells, which express E1A protein, by the calcium- 
phosphate method to propagate the recombinant viruses.30 
High titer of adenovirus stock was prepared by two rounds of 
CsCl-density gradient centrifugation by the published protocol.31 
The presence of the Ad-p53 was confirmed by the two PCR ampli-
fications of p53 exon4 (S: 5'-ATCTACAGTCCCCCTTGCCG-3', 
AS: 5'-GCAACTGACCGTGCAAGTCA-3') and E2B sequence 
in adenovirus (S: 5'-TCGTTTCTCAGCAGCTGTTG-3', AS: 
5'-CATCTGAACTCAAAGCGTGG-3') (Fig. 1). The titer of vi-
ral concentration was determined by plaque forming assay as 
described before.32
3. β-galactosidase staining assay
To determine the transduction efficiency of adenovirus vec-
tor, 5×104 cells/well of ovarian cancer were plated and cul-
tured for 2 days in 6-well plates and then transfected with 0, 
5, 10, 20, and 50 MOIs (multiplicity of infection) of Ad-LacZ 
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Fig. 1. PCR amplification of p53 target sequences in recombinant 
Ad-p53 shows 240 bp product of p53 exon 4 (a), and 850 bp prod-
uct of adenovirus E2B (b). M: size marker, c) positive control for 
p53, d) Ad-Luc, e) negative control.
Fig. 2. Transduction efficiency of adenovirus in ovarian cancer cell 
lines. MOIs of adenovirus with 70-80% transduction efficiency 
were 20 in SKOV3, 5 in OVCAR-3, and 50 in PA-1 cells.
Fig. 3. Sublethal concentration of cisplatin in ovarian cancer cells. 
Concentration of cisplatin with growth inhibition below 10% of the 
control was 0.05μg/ml in SKOV3, OVCAR-3 and PA-1 cells. 
Fig. 4. Western blotting for p53 and p21 protein expressions after 
Ad-p53 shows effective p53 and p21 protein expressions in SKOV3 
cells. OVCAR-3 and PA-1 cells already expressed p53 and p21 
proteins. 
for an hour with serum free media and incubated for addi-
tional 48 hours. After fixation with 0.5% glutaldehyde sol-
ution, β-galactosidase activity was evaluated by incubation 
with X-gal staining solution [5 mM K3Fe(CN)6, 5 mM 
K4Fe(CN)6symbol 183 \f "Symbol" \s 83H2O, 2 ml 5×de-
tergent, 1 mg/ml X-gal, 6.75 ml phosphate buffered saline 
(PBS)](Fig. 2). 
4. Western blot analysis
p53 and p21 protein expressions before and after Ad-p53 
transfer were determined by Western blot analysis. 1×106 
cells were plated in 60 mm dishes for 2 days, transduced with 
Ad-p53, and harvested 2 days after Ad-p53 transfer as de-
scribed before. After solubilization with RIPA buffer (20 mM 
Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% SDS, 1% Triton X-100, 
1% sodium deoxycholate, 2 mM PMSF, 1μg/ml Aprotinin, 
10 mM NaF, 1 mM sodium orthovanadate), proteins were 
separated on 12% acrylamide gel and transferred to nitro-
cellulose filter paper. Specific protein bands were probed with 
anti-p53 and anti-p21 antibodies (Oncoscience p53 Ab-1, 
SC-397, USA) and labelled with anti-mouse antibody [Goat 
anti-mouse IgG (H+L)-AP Conjugated, Bio-Rad]. ECL kit 
(Asherman) was used to visualize the specific bands.
5. Sublethal concentration of cisplatin
To determine the sublethal concentration of cisplatin to in-
hibit cell growth below 10% of the control, 5×104 ovarian 
cancer cells were cultured in 6-well plates for 2 days, and 
treated with serially diluted concentrations of cisplatin. After 
2 days, the cells were harvested and stained with Trypan blue 
solution, and the cell number was counted by hemocytometer 
(Fig. 3). 
6. Cell growth assay
5×104 ovarian cancer cells were cultured in 6-well plates for 
2 days, and treated with Ad-p53 for an hour in serum free 
media. In p53+P group, sublethal concentration of cisplatin 
was added after 24 hours of Ad-p53 transduction, and before 
4 hours of Ad-p53 transduction in P+p53 group. Three con-
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Fig. 5. The growth curves of ovarian cancer cells show growth in-
hibition with Ad-p53 (p53 group) (A, B, C). The synergistic tumor 
growth suppression effect with combination of Ad-p53 and cispla-
tin was observed only in p53+P group of SKOV3 (A) and P+p53 
group of OVCAR-3 cells (B). Growth curve of PA-1 cells did not 
show a synergy with combination of Ad-p53 and cisplatin (C). 
Points: mean; bars: standard error.
trol groups, C, P and Luc were treated with PBS, sublethal 
concentration of cisplatin, and Ad-Luc, respectively. Cells 
were counted daily for 5 days after Trypan blue staining by 
hemocytometer. Each plate was triplicated, and the cell 
growth was reconfirmed by Sulforhodamine B (SRB) assay.33
7. Flow cytometric analysis
1×106 cells/well were cultured for 2 days and treated with 
Ad-p53. Twenty four hours later, the cells were treated with 
5×10−8 gm/ml concentration of cisplatin, further cultured for 
72 hours and analysed with flowcytometry for G2/M phase 
fraction after propidium iodide staining.34 In control and P 
groups, PBS and 5×10−8 gm/ml concentration of cisplatin 
were added to the media, respectively.
RESULTS
1. Transduction efficiencies 
As shown in Fig. 2, the ovarian cancer cell lines showed 
70-80% transduction efficiency with 20 multiplicity of in-
fections (MOIs), 5 MOIs, and 50 MOIs in SKOV3, OVCAR-3, 
and PA-1 cell lines, respectively. 
2. Sublethal concentration of cisplatin 
With 5×10−8 gm/ml concentration of cisplatin, all three 
ovarian cancer cells showed cytotoxic effect below 10% of the 
control (Fig. 3).
3. p53 and p21 expressions after Ad-p53
Western blotting analysis of p53 and p21 protein ex-
pressions after Ad-p53 transfer indicated effective p53 and 
p21 protein expressions in SKOV3 cells. In OVCAR-3 and 
PA-1 cells, however, p53 and p21 proteins were already ex-
pressed before Ad-p53 transfer (Fig. 4). 
4. Cell growth assay
All three ovarian cancer cells manifested growth inhibition 
with Ad-p53 transfer alone, however, the synergy by combina-
tion of Ad-p53 and cisplatin was detected in both SKOV3 and 
OVCAR-3 cells. In SKOV3 cells, Ad-p53 administration fol-
lowed by cisplatin showed a synergistic cytotoxic effect, and 
synergistic cytotoxic effect with reverse treatment was ob-
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Fig. 6. Flow cytometric analysis show that cell fraction at G2/M phase increased after cisplatin treatment in p53 deleted SKOV3 cells, how-
ever, G2/M phase fraction decreased dramatically after Ad-p53 transfer (A). The changes of G2/M phase fraction of OVCAR-3 and PA-1 cells 
were not definitive after cisplatin treatment, but G1/S phase fraction were slightly increased after Ad-p53 transfer (B, C). Legends are the 
same as described in Fig. 5.
served in OVCAR-3 cells (Fig. 5). 
5. Change of cell fraction at G2/M phase with Ad-p53 
transfer
Cell fraction at G2/M phase increased after cisplatin treat-
ment in p53 deleted SKOV3 cells, however, G2/M phase frac-
tion decreased dramatically after Ad-p53 transfer. G2/M 
phase cell fraction of OVCAR-3 and PA-1 cells did not change 
significantly with Ad-p53 transfer (Fig. 6). 
DISCUSSION
The results described herein demonstrated that a combina-
tion of Ad-p53 transfer and cisplatin had a synergistic in-
hibitory effect on growth in ovarian cancer cell lines whose 
p53 gene was either deleted or mutated. In the cells with 
wild-type p53 gene, there was no synergistic cytotoxic effect, 
indicating that the synergy depended on p53 status of the 
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cells. The mechanism of synergistic growth inhibition has 
been known to be due to enhanced sensitivity of the cells to 
cisplatin with restored p53 gene function after wild-type p53 
gene transfer.16,17 Indeed, in SKOV3 and OVCAR-3 cells with 
mutated or deleted p53 gene, restoration of p53 gene function 
with Ad-p53 most likely enhanced the sensitivity of the cells 
to cisplatin. On the other hand, in PA-1 cell line with wild type 
p53 gene, there was no synergistic growth inhibition by com-
bination of Ad-p53 and cisplatin. The lack of synergy in PA-1 
cell line might be due to the fact that there exist certain hither-
to unknown impediments in the expression of the p53-p21 
downstream genes or lack of induction of the chemo- sensi-
tivity mediating factors. Since the whole genetic alteration in 
a specific cell line is not clearly defined, exact mechanisms in-
volved in the response of PA-1 cells can not be offered at 
present. 
Temporal sequence of Ad-p53 and cisplatin administration 
was found to be profoundly important to induce synergistic 
growth inhibition in ovarian cancer cells. In p53 deleted 
SKOV3 cells, the synergy was observed only in the sequential 
administration of Ad-p53 followed by cisplatin, whereas re-
verse sequence was effective in OVCAR-3 cells. The mecha-
nism of dependency of synergy on the sequence of admin-
istration remains unclear, however, as explained below, it ap-
peared to necessitate intact p53-p21 pathway. In p53 deleted 
SKOV3 cells, the synergy was observed after establishment of 
p53-p21 pathway with Ad-p53, which induced p21 protein 
expression. In OVCAR-3 cells, which were already highly ex-
pressing p53 and p21 proteins, the synergy was observed with 
cisplatin administration before Ad-p53 transfer. The depend-
ency of synergy on temporal sequence of Ad-p53 and cisplatin 
administration appeared to involve specific characteristics of 
cancer cells, nevertheless, establishment of p53 gene function 
before cisplatin administration seemed to be the most effec-
tive means to evoke a synergistic growth inhibition in ovarian 
cancer cells. 
Our data showed that the G2/M phase cell fraction of p53 
gene deleted SKOV3 cells increased by cisplatin admin-
istration, but this increase declined dramatically after Ad-p53 
transfer. This result is in good agreement with recent studies 
that p53 protein is also involved in the G2/M cell cycle check 
point, inhibiting cells to progress to additional mitosis, re-
sulting in aneuploidy or polyploidy cells which are sensitive to 
chemotherapeutic agents.25-27 The main mechanism of p53 
gene transfer to cells with non-functioning p53 gene has been 
known to be due to enhanced induction of apoptosis by trans-
ferred p53 protein.35,36 After DNA damage, cells are arrested 
at the G1/S phase of the cell cycle, thus preventing DNA repli-
cations and mitosis in the presence of un-repaired chromoso-
mal alterations.24,25 In the present study, we observed the 
change of DNA ploidy after Ad-p53 transfer in p53 gene de-
leted ovarian cancer cell lines, however, we were not certain 
how much this contributed to the apparent synergistic growth 
inhibitory effect by the combination of Ad-p53 and cisplatin. 
In OVCAR-3 cells with p53 gene mutated, there was no 
change of DNA ploidy with Ad-p53, however, still showed a 
synergy. This conflicting data left us at a loss to explain the 
role of DNA ploidy with regard to chemosensitivity. However, 
it is likely that the change of DNA ploidy might participate 
partly in the synergy of combination of Ad-p53 and cisplatin in 
p53 gene deleted ovarian cancer cell lines.
A limitation of our present study was that we selected three 
ovarian cancer cell lines with different p53 gene status and 
there was no prototype cell line of each p53 gene status. Even 
in a cell line with p53 gene deletion, there might be also other 
unknown genetic alterations necessary for chemosensitivity. 
In addition to other unknown genetic alterations, the diver-
sity of genetic alterations in cancer cell lines would prevent us 
from direct clinical application of knowledge on the combina-
tion of Ad-p53 and cisplatin. Furthermore, we could hardly 
predict the outcome exactly when our study was applied to in 
vivo situations. Further studies with more cell lines of ovarian 
cancer with different p53 gene status are in need. 
 In conclusion, we demonstrated here that a combination of 
adenovirus mediated p53 gene transfer and cisplatin was syn-
ergistic in ovarian cancer cell lines in vitro, and the synergy de-
pended on the p53 gene status and the temporal sequence of 
cisplatin administration. Since p53 gene mutations are quite 
prevalent in ovarian cancer and cisplatin is a commonly used 
chemothrerapeutic agent in human ovarian cancer, the com-
bination of cisplatin and Ad-p53 has been an attractive and 
clinically applicable gene therapy strategy in ovarian cancer.16 
However, our results show that the combination of cisplatin 
and Ad-p53 should be applied judiciously, depending on p53 
status of the cancer cells. Furthermore, the temporal se-
quence of combination may also be selected carefully depend-
ing on p53 gene status. Further study is in need to clarify the 
synergy in in vivo situations.
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